IMMUNOHISTOCHEMISTRY ISOCITRATE DEHYDROGENASE IDH-1 Test
Test Cost: AED 500.0
Test Components
- Price: 500.0 AED
Sample Condition
Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery
Sample: Daily by 6 pm
Report Block: 5 days
Tissue Biopsy: 5 days
Tissue large complex: 7 days
Method
Immunohistochemistry
Test Type
Cancer
Doctor
Oncologist, Pathologist
Test Department
HISTOLOGY
Pre Test Information
Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details
The immunohistochemistry isocitrate dehydrogenase (IDH-1) test is a diagnostic tool used to detect the presence of IDH-1 protein in tissue samples. IDH-1 is an enzyme that plays a crucial role in cellular metabolism and is found in various tissues throughout the body.
Mutations in the IDH-1 gene have been associated with certain types of cancer, most notably gliomas, which are tumors that develop in the brain and spinal cord. The IDH-1 mutation is considered a biomarker for these tumors and can help guide treatment decisions and predict patient prognosis.
The IDH-1 immunohistochemistry test involves staining tissue samples with specific antibodies that can bind to the IDH-1 protein. The presence of the protein is then visualized using a microscope. A positive result indicates the presence of the IDH-1 protein, suggesting the presence of an IDH-1 mutation.
This test is commonly used in pathology laboratories to aid in the diagnosis and classification of gliomas and other IDH-1-associated cancers. It can also be used to monitor treatment response and disease progression in patients with these tumors.
It is important to note that the IDH-1 immunohistochemistry test is just one component of a comprehensive diagnostic workup for cancer patients. Other tests, such as molecular genetic testing and imaging studies, may also be necessary to provide a complete picture of the patient’s condition.
| Test Name | IMMUNOHISTOCHEMISTRY ISOCITRATE DEHYDROGENASE IDH-1 Test |
|---|---|
| Components | |
| Price | 500.0 AED |
| Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
| Report Delivery | Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days |
| Method | Immunohistochemistry |
| Test type | Cancer |
| Doctor | Oncologist, Pathologist |
| Test Department: | HISTOLOGY |
| Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
| Test Details |
The immunohistochemistry isocitrate dehydrogenase (IDH-1) test is a diagnostic tool used to detect the presence of IDH-1 protein in tissue samples. IDH-1 is an enzyme that plays a crucial role in cellular metabolism and is found in various tissues throughout the body. Mutations in the IDH-1 gene have been associated with certain types of cancer, most notably gliomas, which are tumors that develop in the brain and spinal cord. The IDH-1 mutation is considered a biomarker for these tumors and can help guide treatment decisions and predict patient prognosis. The IDH-1 immunohistochemistry test involves staining tissue samples with specific antibodies that can bind to the IDH-1 protein. The presence of the protein is then visualized using a microscope. A positive result indicates the presence of the IDH-1 protein, suggesting the presence of an IDH-1 mutation. This test is commonly used in pathology laboratories to aid in the diagnosis and classification of gliomas and other IDH-1-associated cancers. It can also be used to monitor treatment response and disease progression in patients with these tumors. It is important to note that the IDH-1 immunohistochemistry test is just one component of a comprehensive diagnostic workup for cancer patients. Other tests, such as molecular genetic testing and imaging studies, may also be necessary to provide a complete picture of the patient’s condition. |
